Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry

OBJECTIVES: To evaluate the prevalence of late-onset neutropenia and its complications in patients treated with rituximab (RTX) for rheumatoid arthritis (RA) and other autoimmune diseases (AIDs) in a prospective registry. METHODS: The AutoImmunity and Rituximab registry is an independent 7-year pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmon, J H, Cacoub, P, Combe, B, Sibilia, J, Pallot-Prades, B, Fain, O, Cantagrel, A, Dougados, M, Andres, E, Meyer, O, Carli, P, Pertuiset, E, Pane, I, Maurier, F, Ravaud, P, Mariette, X, Gottenberg, J E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612695/
https://www.ncbi.nlm.nih.gov/pubmed/26509060
http://dx.doi.org/10.1136/rmdopen-2014-000034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612695/
https://www.ncbi.nlm.nih.gov/pubmed/26509060
http://dx.doi.org/10.1136/rmdopen-2014-000034

Ejemplares similares